Free Newsletter
Omnicomm buoyed by e-clinical licensing deals
Licensing contracts have given e-clinical solutions provider OmniComm a big first-half boost. The company reports a 51 percent increase in new tech-transfer licenses over first-half 2009, surpassing $6.9 million. Such licensing accounts for 70 percent of new business while it represents 44 percent for the company's business overall.
Software-as-a-service contracts have shown a "steady increase," according to a statement. The company says also that it has "seen some signs of increased spending in the clinical trial R&D arena."
Omnicomm maintains a roughly even presence in life sciences sectors, including biotech, academic/research, CRO, medical device, and pharma.
- see the Omnicomm earnings release
Related Article:
OmniComm unleashes products, wins
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
SHARE
WITH: